Tokyo-based Daiichi Sankyo said it would join with a mix of foreign multinationals and Japanese companies in sharing clinical trial data with qualified researchers.
The ClinicalStudyDataRequest.com system includes Astellas Pharma, Bayer, Boehringer Ingelheim, Eisai, GlaxoSmithKline ($GSK), Eli Lilly ($LLY), Novartis ($NVS), Roche ($RHBBY), Sanofi ($SNY), Takeda Pharmaceutical, UCB and ViiV Healthcare, majority-owned by GSK, according to its website.
More than a registry, the aim of the system is to lead to research, according to a press release. According to the site, 186 proposals had been submitted to an independent review panel by the end of 2015, with 144 meeting requirements and 82 research projects in progress since May 2013.
|Daiichi Sankyo's Mahmoud Ghazzi|
"Sharing clinical data from trials sponsored by Daiichi Sankyo with qualified researchers helps foster additional scientific insights and provides a mechanism for further understanding of our medicines, which ultimately is a benefit to patient healthcare," Mahmoud Ghazzi, global head of development for Daiichi Sankyo, said in a statement.
In May of last year, the Japan Agency for Medical Research and Development, (AMED) was created in the model of the U.S. NIH as part of a plan to offer as many as 200,000 substance samples from more than 10 drugmakers to universities and other researchers to test for possible therapies.
That effort is one of several by the government of Prime Minister Shinzo Abe as Japan looks to shed decades of deflation by funding research and development in cutting-edge medical device and drug research, including in clinical trials with moves like the development of a patient registry from the National Cancer Center.
- here's the release